Company: CERO
Filing Date: 2025-10-23
Form Type: 424B3
Source: 0001213900-25-101651
Chunk: 13

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-10-23
Form: 424B3
Chunk 13
---
4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                             |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common stock, par value $0.0001 per share                                       |     | CERO              |     | Nasdaq Capital Market                     |
| Warrants, each warrant exercisable for one two-thousandth share of Common Stock |     | CEROW             |     | Nasdaq Capital Market                     |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On October 16, 2025, CERo Therapeutics Holdings, Inc. (the “Company”)
and the requisite Buyers (as defined in the Securities Purchase Agreement) party to the Securities Purchase Agreement (as defined below),
entered into Amendment No. 1 to such Securities Purchase Agreement (the “SPA Amendment”) to add an additional Buyer (as defined
in the Securities Purchase Agreement) and increase the size of the Initial Closing (as defined in the Securities Purchase Agreement) by
$500,000 to an aggregate of approximately $2.25 million of gross proceeds and reduce the size of the Additional Closings (as defined in
the Securities Purchase Agreement) by an offsetting amount. There was no change to the aggregate amount of up to $7 million of proceeds
to be funded pursuant to such Securities Purchase Agreement upon consummation of all of the Closings (as defined in the Securities Purchase
Agreement) provided for therein.

Item 5.03 Amendments to Articles of Incorporation of Bylaws; Change in Fiscal Year.

On October 14, 2025, the Company filed the Certificate
of Designations of Rights and Preferences of the Series E Preferred Stock (the “Certificate of Designations”) for the purpose
of designating and establishing the Company’s Series E convertible preferred stock, par value $0.0001 per share (the “Series
E Preferred Stock”). The